×
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
S&P 500   3,861.22 (-1.00%)
DOW   31,259.33 (-0.57%)
QQQ   288.41 (-1.38%)
AAPL   139.90 (-1.24%)
MSFT   260.43 (-1.68%)
META   167.01 (-1.46%)
GOOGL   2,275.32 (-1.78%)
AMZN   109.33 (-3.44%)
TSLA   717.08 (-2.41%)
NVDA   163.23 (-3.24%)
NIO   22.28 (-2.92%)
BABA   117.77 (-0.81%)
AMD   81.86 (-4.99%)
MU   58.83 (+0.09%)
CGC   3.66 (-3.43%)
T   20.86 (+0.38%)
GE   66.53 (-0.27%)
F   12.05 (+0.08%)
DIS   98.51 (+1.97%)
AMC   13.59 (-3.82%)
PFE   51.09 (-1.52%)
PYPL   74.03 (-2.52%)
NFLX   183.70 (-2.88%)
NASDAQ:LNTH

Lantheus Stock Forecast, Price & News

$65.45
-0.39 (-0.59%)
(As of 06/28/2022 11:28 AM ET)
Add
Compare
Today's Range
$65.40
$67.97
50-Day Range
$55.54
$72.65
52-Week Range
$22.20
$73.78
Volume
15,012 shs
Average Volume
1.19 million shs
Market Capitalization
$4.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.00
30 days | 90 days | 365 days | Advanced Chart

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock Forecast (MarketRank)

Overall MarketRank

2.58 out of 5 stars

Medical Sector

101st out of 1,436 stocks

Diagnostic Substances Industry

1st out of 27 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
Lantheus logo

About Lantheus (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

LNTH Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Company Calendar

Last Earnings
4/29/2022
Today
6/28/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$95.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$91.00
Forecasted Upside/Downside
+45.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-71.28 million
Pretax Margin
-5.81%

Debt

Sales & Book Value

Annual Sales
$425.21 million
Cash Flow
$1.33 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
67,536,000
Market Cap
$4.49 billion
Optionable
Optionable
Beta
0.75














Lantheus Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view top-rated stocks.

What is Lantheus' stock price forecast for 2022?

3 analysts have issued 1 year price targets for Lantheus' stock. Their LNTH stock forecasts range from $91.00 to $100.00. On average, they expect Lantheus' share price to reach $95.00 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts' price targets for Lantheus
or view top-rated stocks among Wall Street analysts.

How has Lantheus' stock price performed in 2022?

Lantheus' stock was trading at $28.89 at the beginning of 2022. Since then, LNTH shares have increased by 126.5% and is now trading at $65.45.
View the best growth stocks for 2022 here
.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Lantheus
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) released its earnings results on Friday, April, 29th. The medical equipment provider reported $0.97 EPS for the quarter, topping the consensus estimate of $0.41 by $0.56. The medical equipment provider had revenue of $208.90 million for the quarter, compared to analysts' expectations of $165.30 million. Lantheus had a positive trailing twelve-month return on equity of 19.83% and a negative net margin of 6.89%. The company's quarterly revenue was up 125.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 EPS.
View Lantheus' earnings history
.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $2.90-$3.15 for the period, compared to the consensus EPS estimate of $2.05. The company issued revenue guidance of $800.00 million-$835.00 million, compared to the consensus revenue estimate of $711.56 million.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.54%), Vanguard Group Inc. (8.37%), State Street Corp (3.48%), Dimensional Fund Advisors LP (2.42%), Lord Abbett & CO. LLC (1.89%) and William Blair Investment Management LLC (1.77%). Company insiders that own Lantheus stock include Andrea Sabens, Brian A Markison, Carol Walker, Cesare Orlandi, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus
.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, Russell Investments Group Ltd., Polar Asset Management Partners Inc., Peregrine Capital Management LLC, Bank of America Corp DE, The Manufacturers Life Insurance Company , and Reinhart Partners Inc.. Company insiders that have sold Lantheus company stock in the last two years include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

Which major investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Lord Abbett & CO. LLC, Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Hood River Capital Management LLC, Penn Capital Management Company LLC, Assenagon Asset Management S.A., and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Lantheus
or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $65.45.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.49 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71.28 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 612 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for Lantheus is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.